Abstract
We appreciate the interest in our publication from Dr. Liao who explained why serum HBV DNA has higher frequency of rtM204I/V mutation than serum HBV RNA in chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogs (NAs). Our study demonstrated that the emergence of serum HBV RNA rtM204I/V mutation was generally delayed compared to that of serum HBV DNA, and both of them would ultimately become nearly 100% mutant forms under continuous NA therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
